Conference paper

PHARMACOGENETICS AND ANTIPSYCHOTICS IN THE LIGHT OF PERSONALIZED PHARMACOTHERAPY

Alma Mihaljević-Peleš ; Department of Psychiatry, University Hospital Centre Zagreb, Zagreb, Croatia
Marina Šagud ; Department of Psychiatry, University Hospital Centre Zagreb, Zagreb, Croatia
Nada Božina ; School of Medicine, University of Zagreb, Clinical Hospital Centre Zagreb
maja Živković ; Neuropsychiatric Hospital “Dr. Ivan Barbot”, Popovača, Croatia
Nikolina Jovanović ; Department of Psychiatry, University Hospital Centre Zagreb, Zagreb, Croatia

Abstract

The concept of personalized drug therapy on the basis of genetic investigations has become a major issue in psychopharmacology. Pharmacogenetic studies have focused on polymorphisms in liver cytochrome P450 isoenzymes that metabolize many antidepressant and antipsychotic medications. The most significant results are the association between drug metabolic polymorphisms of cytochrome P450 with variations in drug metabolic rates and side effects. Additionally, polymorphisms in dopamine and serotonin receptor genes are repeatedly found associated with response phenotypes, probably reflecting the strong affinities that most antipsychotics display for these receptors. The contribution of kinetic factors to the clinical outcome of antipsychotic treatment has a strong evidence base. Genetic tests for the pretreatment prediction of antipsychotic
response have obvious implications for the selection of most appropriate drug and dose and contribute for the optimization of
antipsychotic treatment. The pretreatment determination of individual’s drug metabolic rates by CYP genotyping is the leading field. This review summarizes the present knowledge of associations between cytochrome P450 isoenzymes and the efficacy and side
effects of antipsychotics.

Keywords

pharamacogenetics; antipsychotics; polymorphisms; isoenzymes P450

Hrčak ID:

55852

URI

https://hrcak.srce.hr/55852

Publication date:

30.6.2010.

Visits: 1.519 *